Article Sidebar

Submitted
Apr 22, 2021
Published
Apr 22, 2021
Download
PDF
Statistic
Read Counter : 29 Download : 27

Main Article Content

Abstract

BACKGROUND & OBJECTIVE


Acinetobacter, although saprophytic, the emergence and spread of Acinetobacter in hospital environment is a major area of concern. . It has been associated with a wide variety of illnesses in hospitalized patients, especially patients in the intensive care units. These infections are often difficult to treat, because of the widespread antibiotic resistance. This study is conducted to know the prevalence and drug resistant pattern of Acinetobacter in tertiary care hospital.


MATERIAL & METHODS


 950 isolates of Acinetobacter were obtained from various clinical samples, and subjected to identification by different biochemical tests and antibiotic susceptibility testing by disc diffusion testing by Kirby Baurer method.


RESULT


Out of 950 isolates of Acinetobacter, 82% were Acinetobacter. calcoaceticus baumannii  complex remained 18% were other Acinetobacter spp. Acinetobacter isolates were resistant to important groups of antibiotics tested, including amikacin (50%), gentamycin (65%), tobramycin (38%), ceftriaxone (92%), ceftazidime (80%), cefepime (88%), ampicillin-sulbactum (44%), piperacillin-tazobactum (38%),ciprofloxacin (81%) levofloxacin(82%), imipenem (10%) and trimethoprim-sulfamethoxazole (65%), meropenem (15%), polymixin B (2.2%), colistin (2%).


CONCLUSION


Early detection of MDR Acinetobacter and infection control practices are the best defense against these organisms. Rational use of antimicrobials is an important aspect to delay the emergence of XDR and PDR Acinetobacter spp.

Keywords

Acinetobacter MDR (Multi Drug Resistance) XDR (Extreme Drug Resistance) PDR (Pan Drug Resistance)

Article Details

How to Cite
Jethwa DK, Khokhar ND, & Vegad MM. (2021). Emergence of drug resistance of Acinetobacter at tertiary care hospital. International Journal of Research in Pharmacology & Pharmacotherapeutics, 4(3), 329-333. https://doi.org/10.61096/ijrpp.v4.iss3.2015.329-333
Download Citation
Endnote/Zotero/Mendeley (RIS)
BibTeX

References

  1. [1]. .Dibyendu Banerjee*, Parthasarathi Satpathi, A Silent Invader –Acinetobacter: Picture of a Peripheral Medical College and Hospital of Eastern India. Archives of clinical microbiology; 2011 Vol. 2 No. 4:5
  2. [2]. Mahua Sinha, H. Srinivasa Antibiotic resistance profile & extended spectrum beta-lactamase (ESBL) production in Acinetobacter species. Indian J Med Res 126, July 2007, pp 63-67
  3. [3]. Koneman's Color Atlas and Textbook of Diagnostic Microbiology Elmer W. Koneman, Lippincott Williams & Wilkins, 2006 - Medical - 1565 page
  4. [4]. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing:2012
  5. [5]. Espinal, P., Martí, S., and Vila, J. (2012). Effect of biofilm formation on the survival of Acinetobacter baumannii on dry surfaces. J. Hosp. Infect. 80, 56–60.
  6. [6]. Lee, J. C., Koerten, H., van den Broek, P., Beekhuizen, H., Wolterbeek, R., van den Barselaar, M., van der Reijden, T., van der Meer, J., van de Gevel, J., and Dijkshoorn, L. (2006b). Adherence of Acinetobacter baumannii strains to human bronchial epithelial cells. Res. Microbiol. 157, 360–366.
  7. [7]. Cho, Y. J., Moon, D. C., Jin, J. S., Choi, C. H., Lee, Y. C., and Lee, J. C. (2009). Genetic basis of resistance to aminoglycosides in Acineto bacter spp. and spread of arm A in Acinetobacter baumannii sequence group 1 in Korean hospitals. Diagn. Microbiol. Infect. Dis.64, 185–190.
  8. [8]. Fàbrega, A., Madurga, S., Giralt, E., and Vila, J. (2009). Mechanism of action of and resistance to quinolones. Microb. Biotechnol. 2, 40–61.
  9. [9]. Magiorakos, A. P., Srinivasan, A., Carey, R. B., Carmeli, Y., Falagas, M. E., Giske, C. G., Harbarth, S., Hindler, J. F., Kahlmeter, G., Olsson-Liljequist, B., Paterson, D. L., Rice, L. B., Stelling, J., Struelens, M. J., Vatopoulos, A., Weber, J. T., and Monnet, D. L. (2012). Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin. Microbiol. Infect. 18, 268–281.
  10. [10]. Mohammad Rahbar1, Hadi Mehrgan2, Negar Haji Aliakbari, Prevalence of antibiotic-resistant Acinetobacter baumannii in a 1000-bed tertiary care hospital in Tehran, Iran, ijpm, Year : 2010 | Volume : 53 | Issue : 2 | Page : 290-29
  11. [11]. Paul G. Higgins, Hilmar Wisplinghoff In Vitro Activities of the _-Lactamase Inhibitors Clavulanic Acid, Sulbactam, and Tazobactam Alone or in Combination with _-Lactams against Epidemiologically Characterized Multidrug-Resistant Acinetobacter baumannii Strains antimicrobial agents and chemotherapy, May 2004, p. 15861592 Vol. 48, No. 5
  12. [12]. Vikas Manchanda, Sinha Sanchaita, Multi drug Resistant Acinetobacter; J Glob Infect Dis. 2010 Sep-Dec; 2(3): 291–304.
  13. [13]. Preeti B. Mindolli, Manjunath P. Salmani; Identification And Speciation Of Acinetobacter And Their Antimicrobial Susceptibility Testing; Al Ame en J Med S c i (20 1 0 )3 (4 ) :3 4 5 -3 4 9
  14. [14]. Ignasi Roca, Paula Espinal, The Acinetobacter baumannii oxymoron: commensal hospital dweller turned pan-drug-resistant menace; Microbiology. 23 April 2012 | http://dx.doi.org/10.3389/fmicb.2012.00148
  15. [15]. Falagas, M. E., and Kasiakou, S. K. (2005). Colistin: the revival of polymyxins for the management of multidrug-resistant Gram-negative bacterial infections. C10.